Following the release of Netflix’s Painkiller, the Sackler family’s net worth in 2024 has become a subject of curiosity. Once famous for its contributions to the pharmaceutical and art worlds, the family has recently been under intense scrutiny due to their depiction in the drama series.
The most prominent members of the Sackler clan are Isaac Sackler and Sophie Greenberg, as well as their three sons: Arthur Sackler, Mortimer Sackler, and Raymond Sackler. In addition, Raymond’s son, Richard Sackler, is another key member of the family. In this article, we shall give you all the details of the Sackler family’s net worth in 2024 as well as how they have amassed their fortune.
What is Sackler family’s net worth in 2024?
The Sackler family has an estimated collective net worth of $10.8 Billion in 2024.
Individual Net Worths
- Arthur Sackler Sr.: Deceased, amassed a significant fortune from medical advertising and trade publications. At the time of his death, Arthur’s estate was estimated to be worth $140 million.
- Mortimer Sackler: Deceased, significant donations to various institutions, formerly co-chair of Purdue Pharma. His individual fortune fortune is unknown as of writing.
- Raymond Sackler: Deceased, former CEO of Purdue Pharma, involved in the development of OxyContin. A year before his death in 2017, Raymond and 20 other family members’ net worth was collectively estimated to be around $13 billion.
- Richard Sackler: Eldest son of Raymond, former president of Purdue Pharma, lives in a $1.7 million house in Boca Raton, Florida. Despite selling his $20 million Beverly Hills property, he and the Sackler family remain extraordinarily wealthy.
Sackler family’s earnings explained — how do they make money?
The Sackler family’s wealth primarily comes from their ownership of Purdue Pharma, a pharmaceutical company that developed OxyContin, a prescription painkiller allegedly linked to the opioid crisis. Furthermore, they gain significant income from their investments as well as their secondary pharmaceutical company, Mundipharma.
Purdue Pharma
Purdue Pharma has been the primary source of the Sackler family’s wealth. The company, famous for developing OxyContin, played a significant role in the opioid epidemic. The aggressive promotion and alleged minimization of the drug’s addictive risks led to widespread addiction and numerous lawsuits.
Despite these controversies and ongoing legal challenges, Purdue Pharma generated billions in revenue for the Sackler family. However, following a bankruptcy deal in 2019, they will no longer own the company. Furthermore, Purdue Pharma is set to go a complete restructure and shall be known as Knoa in the future.
Investments
Beyond Purdue Pharma, the Sackler family has spread their wealth through various investments. They own over $1 billion in real estate, another $1 billion in private-equity investments, and $250 million in art, jewelry, and other collectibles. These diverse investments help the Sacklers maintain their financial stability despite facing significant legal challenges.
Mundipharma
Another significant source of income for the Sackler family is Mundipharma, their international pharmaceutical business. As of May 2024, the company’s annual revenue has reached $750 million. Albeit, even Mundipharma is set to be sold under the bankruptcy deal. Consequently, the sale shall seemingly contribute majorly to the Sacklers’ finances.
